Skip to main content
Signal8
Launch Terminal

Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

NASDAQ:XENEHealthcare
-0.35%$37.41
AH$37.41+0.00%vs close
Mkt Cap$3.62B
Float90.76M
O/S96.84M
Vol
$ Vol
RVOL
Inst Own-
SI8.1%
Earnings
Dilution
Xenon Pharmaceuticals Inc. logoNASDAQ:XENE$37.41-0.35%
Phase Distribution
23 lead-sponsored trials·9 active·12 completed
Phase 15
Phase 1/23
Phase 24
Phase 311
Status Overview
Recruiting3
Active, not recruiting6
Completed12
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Terminated

    XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

    XEN496, Placebo

    Epilepsy, Epilepsy in Children +6

    Enrollment
    8
    Start
    Mar 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04639310
  • Phase 3
    Terminated

    An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

    XEN496

    Epilepsy, Epilepsy in Children +6

    Enrollment
    8
    Start
    Aug 2021
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT04912856
  • Phase 3
    Completed

    A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

    XEN1101, Placebo

    Focal Onset Seizures

    Enrollment
    380
    Start
    Nov 2022
    Primary Completion
    Jan 2026
    Completion
    Feb 2026
    NCT05614063
  • Phase 3
    Recruiting

    A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    XEN1101, Placebo

    Primary Generalized Tonic-Clonic Seizures

    Enrollment
    160
    Start
    Feb 2023
    Primary Completion
    Apr 2027est.
    Completion
    Jun 2027est.
    NCT05667142
  • Phase 3
    Recruiting

    A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    XEN1101, Placebo

    Focal Onset Seizures

    Enrollment
    360
    Start
    May 2023
    Primary Completion
    Jan 2028est.
    Completion
    Mar 2028est.
    NCT05716100
  • Phase 3
    Enrolling by invitation

    An Open-label Study of XEN1101 in Epilepsy

    XEN1101

    Focal Epilepsy, Tonic-Clonic Seizures

    Enrollment
    880
    Start
    Apr 2023
    Primary Completion
    Apr 2033est.
    Completion
    Jun 2033est.
    NCT05718817
  • Phase 3
    Active, not recruiting

    A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

    Azetukalner, Placebo

    Major Depressive Disorder

    Enrollment
    450
    Start
    Dec 2024
    Primary Completion
    Oct 2026est.
    Completion
    Dec 2026est.
    NCT06775379
  • Phase 3
    Active, not recruiting

    An Open-Label Study of Azetukalner in Major Depressive Disorder

    Azetukalner

    Major Depressive Disorder

    Enrollment
    460
    Start
    Mar 2025
    Primary Completion
    Jan 2027est.
    Completion
    Mar 2027est.
    NCT06922110
  • Phase 3
    Active, not recruiting

    A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

    Azetukalner, Placebo

    Major Depressive Disorder

    Enrollment
    450
    Start
    Jul 2025
    Primary Completion
    May 2027est.
    Completion
    Jul 2027est.
    NCT07076407
  • Phase 3
    Active, not recruiting

    A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

    Azetukalner, Placebo

    Bipolar Disorder, Bipolar Depression +2

    Enrollment
    400
    Start
    Aug 2025
    Primary Completion
    Jun 2028est.
    Completion
    Aug 2028est.
    NCT07172516
  • Phase 3
    Active, not recruiting

    An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

    Azetukalner

    Bipolar Depression, Bipolar I Disorder +2

    Enrollment
    400
    Start
    Oct 2025
    Primary Completion
    Jun 2029est.
    Completion
    Aug 2029est.
    NCT07217860
  • Phase 2
    Completed

    Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

    XPF-001, placebo

    Dental Pain

    Enrollment
    61
    Start
    Sep 2009
    Primary Completion
    Nov 2009
    Completion
    Dec 2009
    NCT00954356
  • Phase 2
    Completed

    A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

    XPF-002, Placebo

    Postherpetic Neuralgia

    Enrollment
    70
    Start
    Aug 2010
    Primary Completion
    Mar 2011
    Completion
    Mar 2011
    NCT01195636
  • Phase 2
    Active, not recruiting

    A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

    XEN1101

    Focal Epilepsy

    Enrollment
    325
    Start
    Jan 2019
    Primary Completion
    Sep 2021
    Completion
    Oct 2028est.
    NCT03796962
  • Phase 2
    Completed

    A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

    XEN1101 10 mg, XEN1101 20 mg

    Major Depressive Disorder

    Enrollment
    168
    Start
    May 2022
    Primary Completion
    Sep 2023
    Completion
    Oct 2023
    NCT05376150
  • Phase 1/2
    Completed

    Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

    XPF-001, Placebo

    Primary Erythromelalgia, Inherited Erythromelalgia

    Enrollment
    4
    Start
    Apr 2010
    Primary Completion
    Aug 2010
    Completion
    Sep 2010
    NCT01090622
  • Phase 1/2
    Completed

    Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

    XPF-002, Placebo

    Primary Erythromelalgia, Inherited Erythromelalgia

    Enrollment
    8
    Start
    Dec 2011
    Primary Completion
    Apr 2012
    Completion
    May 2012
    NCT01486446
  • Phase 1/2
    Completed

    A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

    XPF-005, Placebo

    Acne Vulgaris

    Enrollment
    213
    Start
    Sep 2015
    Primary Completion
    Feb 2017
    Completion
    Mar 2017
    NCT02656043
  • Phase 1
    Completed

    Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

    XPF-001

    Healthy Human Volunteers

    Enrollment
    64
    Start
    Nov 2008
    Primary Completion
    May 2009
    Completion
    Jul 2009
    NCT00813670
  • Phase 1
    Completed

    Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

    XPF-008, Microcrystalline Cellulose

    Healthy Volunteers

    Enrollment
    130
    Start
    Nov 2017
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT03340220
  • Phase 1
    Completed

    Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

    XEN901, Inert Ingredients Oral Product

    Healthy Volunteers

    Enrollment
    70
    Start
    Feb 2018
    Primary Completion
    Dec 2018
    Completion
    Dec 2018
    NCT03467100
  • Phase 1
    Completed

    Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

    XPF-008, Microcrystalline Cellulose

    Healthy Male Volunteers

    Enrollment
    20
    Start
    Feb 2018
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03468725
  • Phase 1
    Completed

    Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

    14C-XEN1101

    Healthy Volunteers

    Enrollment
    6
    Start
    Jul 2021
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04952467
Search ClinicalTrials.gov for “Xenon Pharmaceuticals”